Sign in →

Test ID POWV Powassan Virus, IgM, Enzyme-Linked Immunosorbent Assay, Serum


Ordering Guidance


For patients with less than 7 days of symptoms, the recommended testing is molecular analysis for detection of Powassan virus (POWV) RNA. Contact either a local Public Health Laboratory or the Centers for Disease Control and Prevention.



Specimen Required


Supplies: Sarstedt 5 mL Aliquot Tube (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.6 mL

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Useful For

Diagnosis of Powassan virus infection.

 

This test should not be used as a screening procedure for the general population.

 

This test should not be used as a "test of cure."

Highlights

This test should be used for patients with at least 7 days of symptoms consistent with Powassan virus (POWV) infection and exposure history.

 

Specimens positive for POWV may require confirmatory testing by a POWV neutralization assay.

Method Name

Enzyme-Linked Immunosorbent Assay (ELISA)

Reporting Name

Powassan Virus, IgM, ELISA, S

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 14 days
  Frozen  30 days

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject
Heat inactivated specimen Reject

Clinical Information

Powassan virus (POWV) is an emerging tick-borne virus, harbored by Ixodes species ticks, which are the same ticks that transmit Lyme disease (Borrelia spp.), Babesia spp., and Anaplasma phagocytophilum, among other pathogens. POWV is a member of the Flavivirus genus, which includes other arthropod-borne viruses (arboviruses) such as West Nile virus and St. Louis encephalitis virus. Two lineages of POWV have been identified, sharing approximately 94% amino acid sequence identity, including Lineage 1, which is the prototypical POWV lineage transmitted by Ixodes marxi and Ixodes cookei, and Lineage 2, which includes deer tick virus and is transmitted by Ixodes scapularis. POWV is maintained in the environment in groundhogs, skunks, squirrels, and white footed mice. Unlike other tick-borne pathogens, following tick attachment to a host, POWV can be transmitted in as little as 15 minutes.

 

Following infection, the incubation period can last anywhere from 4 to 14 days, after which approximately 66% of patients will remain asymptomatic. Symptomatic patients may present with a nonspecific influenza-like illness, including high fever, fatigue, malaise, and myalgia. Approximately 30% of symptomatic patients will progress to develop neurologic manifestations, most commonly encephalitis. While some patients may recover, over 50% of individuals will have persistent neurologic sequelae. POWV has been associated with an overall mortality rate of 10%. Although there is no targeted antiviral therapy and treatment is entirely supportive care, diagnosis is important for a number of reasons, including the ability to discontinue empiric antibiotics and to provide prognostic information for patients and families.

Reference Values

Negative

Reference values apply to all ages.

Interpretation

Negative:

No antibodies to Powassan virus detected. Negative results may occur in samples collected too soon following infection, prior to the development of a robust immune response, or in immunocompromised patients.

 

Positive:

Antibodies to Powassan virus detected. Confirmatory testing through a local public health laboratory and/or the Centers for Disease Control and Prevention is recommended. False positive results may occur in patients with current or prior infection with other flaviviruses (West Nile virus, Zika virus, dengue virus, etc).

Cautions

False-negative results may occur in severely immunosuppressed individuals who are unable to mount a detectable humoral immune response. False-negative results may also occur in samples collected too soon following infection (<7 days post-symptom onset).

 

False-positive results may occur in patients with prior or current infection with other flaviviruses. Contact your local public health laboratory to determine whether confirmatory testing via a neutralization assay is required or recommended.

 

This test should not be used as a "test of cure" as antibodies to Powassan virus (POWV) may persist for months to years after resolution of the infection.

 

This test should be ordered in patients with suspected, symptomatic disease who have had recent exposure to ticks in geographic regions endemic for POWV, including Minnesota, Wisconsin, and the northeast United States. POWV is also prevalent in ticks in Russia and certain regions of Asia.

 

False-positive results may occur in patients screened for POWV who are not at sufficient risk or do not have an exposure history to suggest infection.

Clinical Reference

1. Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Division of Vector-Borne Diseases (DVBD): Powassan virus disease. CDC; Updated January 10, 2019. Available at www.cdc.gov/ticks/tickbornediseases/powassan.html

2. Kemenesi G, Banyai K: Tick-borne Flaviviruses, with a focus on Powassan virus. Clinical Microbiology Reviews. 2019;32(1):e00106-00117

Method Description

The test uses microtiter strips, each with 8 break-off reagent wells coated with recombinant Powassan virus antigens. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgM (also IgA and IgG) antibodies will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate) catalyzing a color reaction.(Unpublished Mayo method)

Day(s) Performed

Tuesday, Thursday

Report Available

Same day/1 to 4 days

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86790

NY State Approved

Yes

Testing Algorithm

For information see the following:

-Meningitis/Encephalitis Panel Algorithm

-Acute Tickborne Disease Testing Algorithm

Forms

If not ordering electronically, complete, print, and send Infectious Disease Serology Test Request (T916) with the specimen.